コーパス検索結果 (1語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 tigen-specific fashion upon conjugation with maytansinoid.
2 that is specific for PSMA conjugated to drug maytansinoid 1 (DM1), a microtubule-depolymerizing compo
3 the maytansinoid antimicrotubule agent drug maytansinoid-1 directly to prostate-specific membrane an
4 gnificance, we report that a clinically used maytansinoid ADC, ado-trastuzumab emtansine (T-DM1), wit
6 lusters required for the biosynthesis of the maytansinoid, ansamitocin, from a cosmid library of Acti
7 ument in favor of IMGN529, a novel anti-CD37 maytansinoid antibody-drug conjugate (ADC), elegantly sh
8 uses trastuzumab to specifically deliver the maytansinoid antimicrotubule agent DM1 to HER2-positive
9 s an immunoconjugate designed to deliver the maytansinoid antimicrotubule agent drug maytansinoid-1 d
11 in and conjugates of potent tubulin poisons (maytansinoids auristatins and taxoids) are undergoing cl
15 amined the metabolic fate in cells of huC242-maytansinoid conjugates containing either a disulfide li
16 ght into the mechanism of action of antibody-maytansinoid conjugates in general, and more specificall
17 Antiproliferative effects of trastuzumab-maytansinoid conjugates were evaluated on cultured norma
18 ing is required for the activity of antibody-maytansinoid conjugates, irrespective of the linker.
21 vitro and in vivo antitumor activity of the maytansinoid DM1 (N(2')-deacetyl-N(2')-(3-mercapto-1-oxo
22 sistance, we conjugated the highly cytotoxic maytansinoid DM1 to antibodies via the maleimidyl-based
23 A) to a potent microtubule-inhibiting agent, maytansinoid DM1, via an intramolecular disulfide bond.
25 tor 2 (HER2) antibody, trastuzumab, with the maytansinoid, DM1, a potent microtubule-disrupting agent
26 al antibody linked to the tubulin-disrupting maytansinoid DM4, in a population of patients with FRalp
31 ped for detection and quantification of free maytansinoid drug in disulfide-linked conjugates between
32 ses of potent anti-tubulins, auristatins and maytansinoids, indiscriminately radiosensitize tumour ce
34 harmacokinetics, and toxicity of trastuzumab-maytansinoid (microtubule-depolymerizing agents) conjuga
35 so identified and characterized the released maytansinoid molecules from these conjugates, and measur
37 h the microtubule-formation inhibitor DM1 (a maytansinoid), or with the DNA alkylator DC1 (a CC1065 a
WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。